IK-930
Based on 5 publication(s) in Google Scholar
IK-930 (compound I-32) is a potent and orally active TEAD inhibitor with an EC50 value of <0.1 µM.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.39%
- CAS No.: 2563892-44-2
- 화학식: C19H19F3N4O2S
- 분자량:424.44
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) IK-930
More-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
RT-PCR
All YAP Isoforms
More
Biological Activity
TEAD[1]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2563892-44-2
-
Appearance Solid
-
분자량 424.44
-
화학식 C19H19F3N4O2S
-
Color White to off-white
-
SMILES
O=S(NC)(C1=CC(C2=CN(C)C=N2)=C(NCC3=CC=C(C(F)(F)F)C=C3)C=C1)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
IK-930 purchased from MedChemExpress. Usage Cited in: Nat Mater. 2026 Feb 20.
IK-930 (0-100 μM; 48 h) inhibited cell viability in NC and VFC T1 and T3 cells.
IK-930 purchased from MedChemExpress. Usage Cited in: Nat Mater. 2026 Feb 20.
IK-930 (30 μM; 48 h) showed representative phase contrast images in NC and VFC T1 and T3 cells.
-
Mol Cell
2025 Sep 18;85(18):3425-3442.e10. PMID: 40914169 -
-
Comput Biol Med
2025 Oct 18;198(Pt B):111201. PMID: 41110298
IK-930 purchased from MedChemExpress. Usage Cited in: Comput Biol Med. 2025 Oct 18;198(Pt B):111201. [Abstract]
IK-930 (0-100 μM) inhibited cell viability with IC50 in the range of 25–158 μM.
IK-930 purchased from MedChemExpress. Usage Cited in: Comput Biol Med. 2025 Oct 18;198(Pt B):111201. [Abstract]
IK-930 (10 μM; 6 days) inhibited cell viability HNSCC cells. Crystal violet cell viability assay of HNSCC cells untreated (Control), treated with vehicle (DMSO) or with 10 μM of TEAD inhibitors for 6 days.
IK-930 purchased from MedChemExpress. Usage Cited in: Comput Biol Med. 2025 Oct 18;198(Pt B):111201. [Abstract]
IK-930 decreased the mRNA expression of CYR61 and CTGF in detrolt-562 and Fadu cells.
-
bioRxiv
2025 Mar 27:2025.03.24.644191. PMID: 40196670
용액&용해도
DMSO : 100 mg/mL (235.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.89 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3560 mL | 11.7802 mL | 23.5605 mL | 58.9011 mL |
| 5 mM | 0.4712 mL | 2.3560 mL | 4.7121 mL | 11.7802 mL | |
| 10 mM | 0.2356 mL | 1.1780 mL | 2.3560 mL | 5.8901 mL | |
| 15 mM | 0.1571 mL | 0.7853 mL | 1.5707 mL | 3.9267 mL | |
| 20 mM | 0.1178 mL | 0.5890 mL | 1.1780 mL | 2.9451 mL | |
| 25 mM | 0.0942 mL | 0.4712 mL | 0.9424 mL | 2.3560 mL | |
| 30 mM | 0.0785 mL | 0.3927 mL | 0.7853 mL | 1.9634 mL | |
| 40 mM | 0.0589 mL | 0.2945 mL | 0.5890 mL | 1.4725 mL | |
| 50 mM | 0.0471 mL | 0.2356 mL | 0.4712 mL | 1.1780 mL | |
| 60 mM | 0.0393 mL | 0.1963 mL | 0.3927 mL | 0.9817 mL | |
| 80 mM | 0.0295 mL | 0.1473 mL | 0.2945 mL | 0.7363 mL | |
| 100 mM | 0.0236 mL | 0.1178 mL | 0.2356 mL | 0.5890 mL |